～論文発表～

1. Long-term survival with nivolumab followed by irinotecan after total gastrectomy in alpha-fetoprotein-producing gastric cancer: a case report and review of the literature.
   Ota T, Sakashita K, Sawada R, Seki K, Maeda H, Tanaka N, Tsujinaka T. Surg Case Rep. 2023 May 8;9(1):71.

2. Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations.
   Noguchi R, Yoshimura A, Uchino J, Takeda T, Chihara Y, Ota T, Hiranuma O, Gyotoku H, Takayama K, Kondo T. Proteomes. 2023;11(1):6.

～学会発表～

1. Evaluation of nivolumab plus ipilimumab with chemotherapy in advanced NSCLC: a single center study.
   Ota T, Tsuya A, Okabe T, Matsui K, Masuda N, Sugiura T, Yonesaka K, Hayashi H, Fukuoka M. 第64回日本肺癌学会学術集会、千葉、O40-7, 2023
2. 局所進行NSCLCに対するCBDCA＋PTX＋nivolumab+TRT併用療法のfeasibility study.
   山中雄太、岡崎優太、中西健太郎、生駒龍興、竹安優貴、勝島詩恵、寺嶋応顕、大田隆代、吉岡弘鎮、倉田宝保.　第64回日本肺癌学会学術集会、千葉、P36-5, 2023
3. Liquid Biopsy からATM遺伝子病的バリアントを認め、既往歴および家族歴から遺伝性腫瘍が疑われた乳癌と膵癌の異時性重複癌の一例.
   大田隆代, 伊田和史、阪本一次 第29日本遺伝性腫瘍学会学術集会、高知、P5-7, 2023
4. Weekly paclitaxel in primary pulmonary angiosarcoma.
   大田隆代、黒崎隆、小川誠人、佐野寿郎、太田善夫、福岡正博. 第20回日本臨床腫瘍学会学術集会、福岡、P7-9, 2023
5. Altered mental status in small cell lung cancer.
   大田隆代、濱田征宏、上野周一、山名正樹、稲森雅幸、宮武望、坂野遼、長谷川喜一、阪本亮、松井薫、益田典幸、福岡正博.第20回日本臨床腫瘍学会学術集会、福岡、p51-2, 2023

～研究会～

1. 実臨床における進行非小細胞肺癌に対するnivolumab, ipilimumab, chemotherapy 併用治療の評価.　
   大田隆代、津谷あすか、岡部崇記、松井薫、益田典幸、杦浦孝宗、米阪仁雄、林秀敏、福岡正博. 第16回肺がん研究会&第14回徳洲会呼吸器部会　症例検討会、東京　9、2023

～論文発表～

1. 1． Disappearance of recurrent thymic epithelial tumor following corticosteroid and cyclosporine treatment: A case report.
   Kurosaki T, Hasegawa Y, Wada Y, Funaki S, Sano H, Fukuoka J, Okimura A, Mukai K, Ishikawa Y, Fukuoka M, Ota T. Respir Investig. 2022;60(2):322-325.

～学会発表～

1. Paraneoplastic Neurological Syndrome in Small Cell Lung Cancer.
   Ota T, Terashima M, Matsui K, Hamada Y, Ueno S, Kobayashi M, Nishide Y, Saito K, Yoshida Y, Tada N, Masuda N, Fukuoka M. IASLC 2022 Asia Conference on Lung Cancer, Nara, PP02.49, 2022
2. Long-term survival with nivolumab and irinotecan after total gastrectomy in alpha-fetoprotein-producing gastric cancer.
   大田隆代, 坂下克也, 雪本清隆, 文元雄一, 澤田隆吾, 橋村俊哉, 関来未, 沖村明, 田中紀子, 前田裕之, 大平友弘, 徳永正弘, 辻仲利政, 福岡正博. 第19回日本臨床腫瘍学会学術集会、京都、P10-2, 2022
3. Adrenocortical carcinoma mimics metastatic gastric adenocarcinoma.
   大田隆代, 雪本清隆, 高橋諒, 坂下克也, 三浦光太郎, 関来未, 梶川竜治, 藤本俊輔, 今村修三, 宮武望, 田中紀子, 前田裕之, 大平友弘, 徳永正弘, 覚道健一, 辻仲利政, 福岡正博. 第19回日本臨床腫瘍学会学術集会、京都、P30-10, 2022

～論文発表～

1. Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.　
   Ota T, Okabayashi A, Fukuoka M. Respirol Case Rep. 2021;9(10):e0841.
2. Interstitial lung disease associated with adjuvant and neoadjuvant chemotherapy in early breast cancer.
   Tezuka K, Miura K, Nakano Y, Ueda T, Yagyu K, Matsuyama S, Shirai M, Okuda H, Ujikawa M, Ota T. World J Surg Oncol. 2021;19(1):169.

～学会発表～

1. Osimertinib induced cardiomyopathy.
   大田隆代、笠松慶子、松井薫、寺嶋応顕、長谷川喜一、福岡正博.　第62回日本肺癌学会学術集会、横浜、P9-6-4, 2021
2. BRAF/MEK阻害剤に劇的な効果をみとめたBRAF遺伝子変異を有する肺腺癌の一例.
   Ota T, Okabayashi A, Fukuoka M.　第59回日本癌治療学会学術集会、横浜, P24-6, 2021
3. 辺縁系脳炎を合併した小細胞肺癌の一例.
   大田隆代、松井薫、濱田征宏、上野周一、益田典幸、福岡正博.　第113回日本肺癌学会関西支部会、京都、52, 2021
4. Serum β2 microglobulin with pembrolizumab in non-small cell lung cancer.
   Ota T, Kudo K, Uchino J, Seto Y, Terashima Y, Nakano Y, Okabe T, Sugiura T, Hasegawa Y, Tsuya A, Fukuoka M. 第18回日本臨床腫瘍学会学術集会, 京都, PD1-2-4, 2021
5. Altered state of consciousness in small cell lung cancer.
   Ota T, Matsui K, Hamada Y, Ueno S, Masuda N, Fukuoka M. 第18回日本臨床腫瘍学会学術集会、京都, P47-7, 2021
6. ステロイドパルス療法で完全消失した再発胸腺腫瘍の一例.
   Kurosaki T, Hasegawa Y, Wada Y, Funaki S, Okimura A, Mukai K, Ishikawa Y, Ota T, Fukuoka M. 第18回日本臨床腫瘍学会学術集会、京都, P57-6, 2021

～論文発表～

1. Serum immune modulators during the first cycle of anti-PD-1 antibody therapy in non-small cell lung cancer: Perforin as a biomarker.
   Ota T, Fukui T, Nakahara Y, Takeda T, Uchino J, Mouri T, Kudo K, Nakajima S, Suzumura T, Fukuoka M. Thorac Cancer. 2020;11(11): 3223-3233.　
2. False-positive elevation of CK-MB levels with chest pain in lung adenocarcinoma.
   Ota T, Hasegawa Y, Murata E, Tanaka N, Fukuoka M. Case Rep Oncol. 2020;13(1): 100-104.

～学会発表～

1. 肺腺癌に対する免疫チェックポイント阻害剤投与に関連した脳症の一例.
   Ota T, Hamada Y, Ueno S, Fukuoka M. 第58回日本癌治療学会学術集会、京都, P-209, 2020
   

～論文発表～

1. Successful Desensitization With Crizotinib After Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma.
   Ota T, Masuda N, Matsui K, Yamada T, Tanaka N, Fujimoto S, Fukuoka M. Intern Med. 2019; 58(18), 2651-5.
2. A Systematic Review of Observational Studies of Trifluridine/Tipiracil (TAS-102) for Metastatic Colorectal Cancer.
   Andersen SE, Andersen IB, Jensen BV, Pfeiffer P, Ota T, Larsen JS. Acta Oncol. 2019; 58(8), 1149-57.

～学会発表～

1. Serum baseline perforin levels with anti-PD-1 antibody therapies in non-small cell lung cancer.
   Ota T, Fukui T, Nakahara Y, Takeda T, Uchino J, Mouri T, Kudo K, Nakajima S, Suzumura T, Fukuoka M. The 60th Annual Meeting of the Japan Lung Cancer Society, Osaka, IS13-3, 2019
2. Acute kidney injury with pembrolizumab in lung adenocarcinoma.
   Ota T, Masuda N, Hasegawa Y, Terashima M, Tsuya A, Matsui K, Fukuoka M. The 60th Annual Meeting of the Lung Cancer Society, Osaka, P5-39, 2019
3. Serum baseline perforin levels with anti-PD-1 antibody therapies in non-small cell lung cancer.
   Ota T, Fukui T, Nakahara Y, Takeda T, Uchino J, Mouri T, Kudo K, Nakajima S, Suzumura T, Fukuoka M. The 57th Annual Meeting of Japan Society of Clinical Oncology, Fukuoka, IO3-4, 2019
4. Serum perforin levels during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer.
   Ota T, Fukui T, Nakahara Y, Takeda T, Uchino J, Mouri T, Kudo K, Nakajima S, Suzumura T, Okabe T, Hayashi H, Miyatake N, Nakano Y, Terashima M, Hasegawa T, Tsukuda H, Matsui K, Masuda N, Fukuoka M. IASLC 2019 WCLC, Barcelona, P1.04-40, 2019
5. Successful desensitization with crizotinib after crizotinib-induced liver injury in ROS1-rearranged lung adenocarcinoma.
   大田隆代,　益田典幸、山田孝雄、田中紀子、藤本俊輔、宮武望、中野雄介、寺嶋応顕、長谷川喜一、佃博、松井薫、福岡正博. 第17回日本臨床腫瘍学会学術集会、京都、P1-071, 2019

～論文発表～

1. Porous diaphragm syndrome with recurrent thymoma.
   Ota T, Hasegawa Y, Okabe T, Okimura A, Fukuoka M. Respirol Case Rep. 2018;7(2): e00391.
2. Breast metastasis from EGFR-mutated lung adenocarcinoma: a case report and review of the literature.
   Ota T, Hasegawa Y, Okimura A, Sakashita K, Sunami T, Yukimoto K, Sawada R, Sakamoto K, Fukuoka M. Clin Case Rep. 2018;6(8):1510-6.
3. Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer.　
   Ota T, Miyatake N, Tanaka N, Hasegawa Y, Tokunaga M, Tsukuda H, Fukuoka M. Gynecol Endocrinol. 2018;34(4):286-289.

～学会発表～

1. Serum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer.
   Ota T, Takeda T, Fukui T, Nakahara Y, Kudo K, Okabe T, Hayashi H, Otani S, Hiyoshi Y, Yonesaka K, Sugiura T, Suzumura T, Terashima M, Nakano Y, Hasegawa Y, Tsukuda H, Matsui K, Masuda N, Fukuoka M. ESMO 2018 Congress, Munich, 1200P, 2018
2. 胸腺腫に合併症した横隔膜交通症の一例.
   大田隆代、長谷川喜一、岡部崇記、沖村明、宮武望、中野雄介、寺嶋応顕、佃博、松井薫、益田典幸、福岡正博.　第16回日本臨床腫瘍学会、神戸、P2-194, 2018
3. During the First Cycle of Serum Perforin Predicts Efficacy of Anti-PD1 Antibody Therapies in Non-Small Cell Lung Cancer.
   Ota T, Takeda T, Fukui T, Nakahara Y, Kudo K, Okabe T, Hayashi H, Otani S, Hiyoshi Y, Yonesaka K, Sugiura T, Suzumura T, Miyamoto A, Terashima M, Nakano Y, Hasegawa Y, Tsukuda H, Matsui K, Masuda N, Fukuoka M. The 6th JCA-AACR, Kyoto, 6-6, 2018